Standard Opioid
Phase 3Small molecule
Standard Opioid is one of 9 small molecule programs targeting Ventral Hernia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Ventral Hernia
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Robaxin
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Standard Opioid
PPrisma Health-Upstate
Phase 3
AGN-151607-DP
AbbViePhase 2
Entereg
Merck & Co.Preclinical
Naropin
FFresenius Kabi USA, LLC
Preclinical
Bupivicaine
TThomas Jefferson University
Preclinical
Prophylactic
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Standard Opioid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPrisma Health-Upstate